Nous-209 neoantigen vaccine for cancer prevention in Lynch Syndrome carriers: a phase 1b/2 trial

Elisa Scarselli, Direttore scientifico e cofondatore Nouscom Srl, terrà un seminario dal titolo "Nous-209 neoantigen vaccine for cancer prevention in Lynch Syndrome carriers: a phase 1b/2 trial".

La dottoressa Scarselli è una scienziata esperta di vaccini. Ha lavorato sull'infezione da epatite C e sull'immunità ed in seguito ha svolto ricerche anche nel campo dell'oncologia. E' alla direzione scientifica di quattro programmi preclinici nel campo dell'immunoterapia del cancro.

Abstract

Cancer interception is a preventive strategy aimed at lowering cancer incidence by targeting premalignant lesions. Lynch syndrome (LS), one of the most prevalent hereditary cancer syndromes, is caused by germline mutations in DNA mismatch repair (MMR) genes. Deficiency in MMR results in microsatellite instability (MSI) and accumulation of frameshift peptide (FSP) neoantigens, commonly shared across MSI tumors and precancerous lesions. Nous-209 is an off-the-shelf immunotherapy using Great Ape Adenoviral (GAd) and Modified Vaccinia Ankara (MVA) encoding 209 FSP shared in MSI tumors. Here, we present the final Phase Ib/II trial results in LS carriers (N=45) including evaluation of a primary vaccination and revaccination at 1 year, reporting safety, immunogenicity, and initial signals of clinical activity.

Ospita il professore Nicola Zambrano